I can't vote since I have shares in €, but if I could, I would only vote yes if a deal materialises until the meeting and/or the purpose of the increase is explained - in the video, Nader isn't really clear on this (he says that 100m would be the maximum amount until commercialisation if they went alone without any deal, which he believes won't happen, AND that the shares are for opportunities (acquisitions?) that cross their way).

No to all further incentives until they have created some shareholder value.

If we can't get a deal with a decent upfront-payment, I wouldn't mind if they put the company for sale in a stock swap deal. This way we can participate from the value of Leronlimab in the hands of someone who can run all the trials for multiple indications simultaneously and much quicker.